Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer

LESSONS LEARNED. Panitumumab shows activity in terms of disease control rate and preventing disease progression but not for tumor shrinkage in head and neck squamous cell cancer for second‐line treatment. Epidermal growth factor receptor (EGFR) copy number gain, a property of tumor cells that theore...

Descripción completa

Detalles Bibliográficos
Autores principales: Siano, Marco, Molinari, Francesca, Martin, Vittoria, Mach, Nicolas, Früh, Martin, Freguia, Stefania, Corradino, Irene, Ghielmini, Michele, Frattini, Milo, Espeli, Vittoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507653/
https://www.ncbi.nlm.nih.gov/pubmed/28592616
http://dx.doi.org/10.1634/theoncologist.2017-0069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507653/
https://www.ncbi.nlm.nih.gov/pubmed/28592616
http://dx.doi.org/10.1634/theoncologist.2017-0069

Ejemplares similares